S. PORRU, M. MONACO, G. SPITERI, A. CARTA, G. CALISKAN, C. VIOLÁN, P. TORÁN-MONSERRAT, L. VIMERCATI, S. TAFURI, P. BOFFETTA, F. VIOLANTE, E. SALA, E. SANSONE, F. GOBBA, L. CASOLARI, A. WIESER, C. JANKE, A. TARDON, M. RODRIGUEZ-SUAREZ, F. LIVIERO, M. SCAPELLATO, M. DELL'OMO, N. MURGIA, D. MATES, V. CALOTA, J. STRHÁRSKY, M. MRÁZOVÁ, E. PIRA, A. GODONO, G. MAGNANO, C. NEGRO and G. VERLATO Aten Primaria.2022 Aug; 54(9):102437.doi:10.1007/s44197-023-00139-8 PMID:37480426
BackgroundSARS-CoV-2 breakthrough infections (BI) after vaccine booster dose are a relevant public health issue.MethodsMulticentric longitudinal cohort study within the ORCHESTRA project, involving 63,516 health workers (HW) from 14 European settings. The study investigated the cumulative incidence of SARS-CoV-2 BI after booster dose and its correlation with age, sex, job title, previous infection, and time since third dose.Results13,093 (20.6%) BI were observed. The cumulative incidence of BI was higher in women and in HW aged < 50 years, but nearly halved after 60 years. Nurses experienced the highest BI incidence, and administrative staff experienced the lowest. The BI incidence was higher in immunosuppressed HW (28.6%) vs others (24.9%). When controlling for gender, age, job title and infection before booster, heterologous vaccination reduced BI incidence with respect to the BNT162b2 mRNA vaccine [Odds Ratio (OR) 0.69, 95% CI 0.63-0.76]. Previous infection protected against asymptomatic infection [Relative Risk Ratio (RRR) of recent infection vs no infection 0.53, 95% CI 0.23-1.20] and even more against symptomatic infections [RRR 0.11, 95% CI 0.05-0.25]. Symptomatic infections increased from 70.5% in HW receiving the booster dose since < 64 days to 86.2% when time elapsed was > 130 days.ConclusionsThe risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics.
D. ABIÉTAR, B. ARAGÓN, F. ORFILA and R. ALMIRALL Aten Primaria.2022 Aug; 54(9):102437.doi: PMID:
M. CARMONA-CERVELLÓ, B. LEÓN-GÓMEZ, N. LAMONJA-VICENTE, R. DACOSTA-AGUAYO, A. ROGER, A. REYNÉS, V. PUTIN, C. FORS and P. MONSERRAT Aten Primaria.2022 Aug; 54(9):102437.doi: PMID:
A. BRUGUERA, Y. DÍAZ, L. CARRASCO, A. ROSO-LLORACH, D. NOMAH, S. MORENO-FORNÉS, C. VIOLÁN, J. CASABONA and J. MIRÓ Aten Primaria.2022 Aug; 54(9):102437.doi: PMID:
M. HEUMANN, G. RÖHNSCH, E. ZABALETA-DEL-OLMO, B. TOSO, L. GIOVANELLA and K. HÄMEL Aten Primaria.2022 Aug; 54(9):102437.doi:10.1111/hex.13843 PMID:37565592
BackgroundMost health systems are insufficiently prepared to promote the participation of chronically ill patients in their care. Strong primary health care (PHC) strengthens patients’ resources and thus promotes their participation. The tasks of providing continuous care to people with chronic diseases and promoting self-management are the responsibility of PHC nurses. Recent research assessing enablers of or barriers to nurses’ efforts to support patients’ participation has mostly not considered the special situation of patients with chronic diseases or focused on the PHC setting. ObjectiveTo investigate enablers of and barriers to PHC nurses’ efforts to promote the participation of chronically ill patients in their care. MethodsWe interviewed 34 practicing PHC nurses and 23 key informants with advanced knowledge of PHC nursing practice in Brazil, Germany and Spain. The data was analyzed using thematic coding. ResultsWe identified four categories of barriers and enablers. (1) Establishing bonds with patients: Interviewees emphasized that understanding patients’ views and behaviours is important for PHC nurses. (2) Cooperation with relatives and families: Good relationships with families are fundamental, however conflicts within families could challenge PHC nurses efforts to strengthen participation. (3) Communication and cooperation within PHC teams: PHC nurses see Cooperative team structures as a potential enabler, while the dominance of a ‘biomedical’ approach to patient care is seen as a barrier. (4) Work environment: Interviewees agreed that increased workload is a barrier to patient participation. Discussion and ConclusionsSupporting patient participation should be acknowledged as an important responsibility for nurses by general practitioners and PHC planners. PHC nurses should be trained in communicative competence when discussing participation with chronically ill patients. Interprofessional education could strengthen other professionals’ understanding of patient participation as a nursing task. Patient or Public ContributionThis study is part of a research project associated with the research network ‘forges: User-oriented care: Promotion of health in the context of chronic diseases and care dependency’. The study’s focus and provisional results were discussed continuously with partners in health and social care practice and presented to and discussed with the public at two conferences in which patient representatives, professionals and researchers participated.
C. VIOLÁN, L. CARRASCO-RIBELLES, G. COLLATUZZO, G. DITANO, M. ABEDINI, C. JANKE, C. REINKEMEYER, L. GIANG, F. LIVIERO, M. SCAPELLATO, M. MAURO, F. RUI, S. PORRU, G. SPITERI, M. MONACO, A. CARTA, M. OTELEA, A. RASCU, E. FABIÁNOVÁ, Z. KLÖSLOVÁ, P. BOFFETTA and P. TORÁN-MONSERRAT Aten Primaria.2022 Aug; 54(9):102437.doi:10.3390/vaccines11081340 PMID:37631908
Understanding antibody persistence concerning multimorbidity is crucial for vaccination policies. Our goal is to assess the link between multimorbidity and serological response to SARS-CoV-2 nine months post-first vaccine. We analyzed Healthcare Workers (HCWs) from three cohorts from Italy, and one each from Germany, Romania, Slovakia, and Spain. Seven groups of chronic diseases were analyzed. We included 2941 HCWs (78.5% female, 73.4% & GE; 40 years old). Multimorbidity was present in 6.9% of HCWs. The prevalence of each chronic condition ranged between 1.9% (cancer) to 10.3% (allergies). Two regression models were fitted, one considering the chronic conditions groups and the other considering whether HCWs had diseases from & GE;2 groups. Multimorbidity was present in 6.9% of HCWs, and higher 9-months post-vaccine anti-S levels were significantly associated with having received three doses of the vaccine (RR = 2.45, CI = 1.92-3.13) and with having a prior COVID-19 infection (RR = 2.30, CI = 2.15-2.46). Conversely, lower levels were associated with higher age (RR = 0.94, CI = 0.91-0.96), more time since the last vaccine dose (RR = 0.95, CI = 0.94-0.96), and multimorbidity (RR = 0.89, CI = 0.80-1.00). Hypertension is significantly associated with lower anti-S levels (RR = 0.87, CI = 0.80-0.95). The serological response to vaccines is more inadequate in individuals with multimorbidity.
Troncoso-Mariño A, Lestón Vázquez M, Gallardo Borge S, Del Val Garcia JL, Amado Guirado E and Violán C Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.aprim.2023.102651 PMID:37187104
PURPOSE: To compare the effect of discontinuing bisphosphonate treatment on fracture risk in postmenopausal women at high versus low risk of fracture. DESIGN: Retrospective, longitudinal and population-based cohort study. SETTING: Barcelona City Primary Care. Catalan Health Institute. PARTICIPANTS: All women attended by primary care teams who in January 2014 had received bisphosphonate treatment for at least five years were included and followed for another five years. INTERVENTION: Patients were classified according to their risk of new fractures, defined as those who had a history of osteoporotic fracture and/or who received treatment with an aromatase inhibitor, and the continuity or deprescription of the bisphosphonate treatment was analyzed over fiver year follow-up. MAIN MEASUREMENTS: The cumulative incidence of fractures and the incidence density were calculated and analyzed using logistic regression and Cox models. RESULTS: We included 3680 women. There were no significant differences in fracture risk in high-risk women who discontinued versus continued bisphosphonate treatment (hazard ratio [HR] 1.17, 95% confidence interval [CI] 0.87-1.58 for total osteoporotic fractures). However, discontinuers at low risk had a lower incidence of fracture than continuers. This difference was significant for vertebral fractures (HR 0.64, 95% CI 0.47-0.88) and total fractures (HR 0.77, 95% CI 0.64-0.92). CONCLUSION: Our results suggest that deprescribing bisphosphonates in women who have already received five years of treatment does not increase fracture risk. In low-risk women, continuing this treatment might could even favor the appearance of new osteoporotic fractures.
B. LEÓN-GÓMEZ, E. MORENO-GABRIEL, L. CARRASCO-RIBELLES, C. FORS and L. LIUTSKO Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.gaceta.2023.102315 PMID:37418947
[No abstract available]
M. SANCHEZ-DURÁN, N. MAIZ, L. LIUTSKO, J. BIELSA-PASCUAL, R. GARCÍA-SIERRA, A. ZIENTALSKA, I. VELASCO, E. VAZQUEZ, O. GRACIA, A. RIBAS, N. SITJA, M. NADALES, C. MARTINEZ, A. GONCE, M. FRICK, M. GUERRERO-MARTÍNEZ, C. VIOLÁN, P. TORÁN, G. FALGUERA-PUIG, R. GOL and CITEMB Grp Aten Primaria.2022 Aug; 54(9):102437.doi:10.1136/bmjopen-2023-071997 PMID:37474185
IntroductionCongenital cytomegalovirus (cCMV) is the leading cause of non-genetic sensorineural hearing loss and one of the main causes of neurological disability. Despite this, no universal screening programme for cCMV has been implemented in Spain. A recent study has shown that early treatment with valaciclovir, initiated in the first trimester and before the onset of signs in the fetus, reduces the risk of fetal infection. This finding favours the implementation of a universal screening programme for cCMV.The aim of this study is to evaluate the performance of a universal screening programme for cCMV during the first trimester of pregnancy in a primary care setting. Methods and analysisThis is an observational multicentre cohort study. The study will be conducted in four primary care settings from the Northern Metropolitan Barcelona area and three related hospitals and will last 3 years and will consist of a recruitment period of 18 months.In their first pregnancy visit, pregnant women will be offered to add a CMV serology test to the first trimester screening tests. Pregnant women with primary infection will be referred to the reference hospital, where they will continue treatment and follow-up according to the clinical protocol of the referral hospital, which includes treatment with valacyclovir. A CMV-PCR will be performed at birth on newborns of mothers with primary infection, and those who are infected will undergo neonatal follow-up for at least 12 months of life.For the analysis, the acceptance rate, the prevalence of primary CMV infections and the CMV seroprevalence in the first trimester of pregnancy will be studied. Ethics and disseminationEthical approval was obtained from the University Institute Foundation for Primary Health Care Research Jordi Gol i Gurina Ethics Committee 22/097-P dated 27 April 2022.
M. LEJEUNE, L. REVERTÉ, N. GALLARDO, E. SAURAS, R. BOSCH, D. MATA, A. ROSO, A. PETIT, V. PEG, F. RIU, J. GARCIA-FONTGIVELL, F. RELEA, B. VIEITES, L. DE LA CRUZ-MERINO, M. ARENAS, V. RODRIGUEZ, J. GALERA, A. KORZYNSKA, B. PLANCOULAINE, T. ALVARO and C. LÓPEZ Aten Primaria.2022 Aug; 54(9):102437.doi:10.3390/ijms241411297 PMID:37511057
Triple-negative breast cancer (TNBC) is particularly challenging due to the weak or absent response to therapeutics and its poor prognosis. The effectiveness of neoadjuvant chemotherapy (NAC) response is strongly influenced by changes in elements of the tumor microenvironment (TME). This work aimed to characterize the residual TME composition in 96 TNBC patients using immunohistochemistry and in situ hybridization techniques and evaluate its prognostic implications for partial responders vs. non-responders. Compared with non-responders, partial responders containing higher levels of CD83+ mature dendritic cells, FOXP3+ regulatory T cells, and IL-15 expression but lower CD138+ cell concentration exhibited better OS and RFS. However, along with tumor diameter and positive nodal status at diagnosis, matrix metalloproteinase-9 (MMP-9) expression in the residual TME was identified as an independent factor associated with the impaired response to NAC. This study yields new insights into the key components of the residual tumor bed, such as MMP-9, which is strictly associated with the lack of a pathological response to NAC. This knowledge might help early identification of TNBC patients less likely to respond to NAC and allow the establishment of new therapeutic targets.